Convergence of the two pandemics: metabolic syndrome and COVID-19 over last two years
has posed unprecedented challenges to individuals as well as healthcare systems …

Diabetes, a chronic metabolic disorder disrupting blood sugar regulation, has emerged as a
prominent silent pandemic. Uncontrolled diabetes predisposes an individual to develop fatal …

Background Dapagliflozin has been proposed as a potential treatment for coronavirus
disease 2019 (COVID-19) by reducing cytokine production and inflammation. However …

Background and Objectives: The COVID-19 pandemic caused by the Coronavirus SARS-
CoV-2 is a complex challenge for the existing scientific and medical landscape. It is an …

Background Hyperglycaemia is associated with worse outcomes in many settings. However,
the association between dysglycaemia and adverse outcomes remains debated in COVID …

Aim To explore the impact of type 2 diabetes (T2D), glycaemic control and use of glucose‐
lowering medication on clinical outcomes in hospitalized patients with COVID‐19. Materials …

Introduction People with type 2 diabetes are at heightened risk for severe outcomes related
to COVID-19 infection, including hospitalization, intensive care unit admission, and mortality …

Coronavirus disease 2019 (COVID-19) is a severe respiratory syndrome caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Heart failure (HF) is associated …

Objective To evaluate the relationship between metformin and the outcome of COVID-19
infection. Methods The study included 413 patients with type 2 diabetes among the 5,217 …

Objective Critical illness is often accompanied by elevated blood glucose, which generally
correlates with increased morbidity and mortality. Prehospital blood glucose (PBG) level …